ATE257703T1 - 1,3-thiazole als adenosine a3 rezeptor antagonisten zur behandlung von asthma, allergien und diabetes - Google Patents

1,3-thiazole als adenosine a3 rezeptor antagonisten zur behandlung von asthma, allergien und diabetes

Info

Publication number
ATE257703T1
ATE257703T1 AT98950388T AT98950388T ATE257703T1 AT E257703 T1 ATE257703 T1 AT E257703T1 AT 98950388 T AT98950388 T AT 98950388T AT 98950388 T AT98950388 T AT 98950388T AT E257703 T1 ATE257703 T1 AT E257703T1
Authority
AT
Austria
Prior art keywords
adenosine
asthma
thiazoles
allergies
diabetes
Prior art date
Application number
AT98950388T
Other languages
English (en)
Inventor
Shigenori Ohkawa
Hiroyuki Kimura
Naoyuki Kanzaki
Original Assignee
Takeda Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Chemical Industries Ltd filed Critical Takeda Chemical Industries Ltd
Application granted granted Critical
Publication of ATE257703T1 publication Critical patent/ATE257703T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)
AT98950388T 1997-10-27 1998-10-26 1,3-thiazole als adenosine a3 rezeptor antagonisten zur behandlung von asthma, allergien und diabetes ATE257703T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP29448597 1997-10-27
PCT/JP1998/004837 WO1999021555A2 (en) 1997-10-27 1998-10-26 Adenosine a3 receptor antagonists

Publications (1)

Publication Number Publication Date
ATE257703T1 true ATE257703T1 (de) 2004-01-15

Family

ID=17808383

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98950388T ATE257703T1 (de) 1997-10-27 1998-10-26 1,3-thiazole als adenosine a3 rezeptor antagonisten zur behandlung von asthma, allergien und diabetes

Country Status (8)

Country Link
US (2) US6436966B1 (de)
EP (1) EP1027050B1 (de)
JP (1) JPH11193281A (de)
AT (1) ATE257703T1 (de)
AU (1) AU9648098A (de)
CA (1) CA2302417A1 (de)
DE (1) DE69821132T2 (de)
WO (1) WO1999021555A2 (de)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11193281A (ja) * 1997-10-27 1999-07-21 Takeda Chem Ind Ltd アデノシンａ３受容体拮抗剤およびチアゾール化合物
WO1999064418A1 (en) * 1998-06-05 1999-12-16 Novartis Ag Aryl pyridinyl thiazoles
IL146105A (en) * 1999-04-23 2005-09-25 Tadeda Pharmaceutical Company 5-pyridyl-1, 3-azole compounds, process for producing the same and use therefor
EP1205478A4 (de) * 1999-08-06 2004-06-30 Takeda Chemical Industries Ltd INHIBITOREN DER p38MAP-KINASE
AU7559200A (en) * 1999-10-12 2001-04-23 Japan Tobacco Inc. Hypertriglyceridemia remedies and antiobestics
ATE311385T1 (de) * 1999-10-27 2005-12-15 Novartis Pharma Gmbh Thiazol und imidazo(4,5-b)pyridin verbindungen und ihre verwendung als pharmazeutika
CA2395564A1 (en) 1999-11-22 2001-05-31 Smithkline Beecham Plc Novel compounds
CA2397661C (en) * 2000-03-01 2012-01-03 Janssen Pharmaceutica N.V. 2,4-disubstituted thiazolyl derivatives
GB0005357D0 (en) 2000-03-06 2000-04-26 Smithkline Beecham Plc Compounds
CA2404384A1 (en) * 2000-03-30 2001-10-11 Takeda Chemical Industries, Ltd. Substituted 1,3-thiazole compounds, their production and use
HUP0700086A2 (en) * 2000-08-11 2007-05-29 Eisai Co Ltd 2-aminopyridine compounds, use thereof as drugs and pharmaceutical compositions containing them
US6645990B2 (en) 2000-08-15 2003-11-11 Amgen Inc. Thiazolyl urea compounds and methods of uses
WO2002024680A1 (en) 2000-09-21 2002-03-28 Smithkline Beecham P.L.C. Imidazole derivatives as raf kinase inhibitors
GB0028383D0 (en) 2000-11-21 2001-01-03 Novartis Ag Organic compounds
WO2002046186A1 (en) 2000-12-08 2002-06-13 Takeda Chemical Industries, Ltd. Substituted thiazole derivatives bearing 3-pyridyl groups, process for preparing the same and use thereof
WO2002062792A1 (en) * 2001-02-02 2002-08-15 Takeda Chemical Industries, Ltd. Jnk inhibitor
GB0102668D0 (en) * 2001-02-02 2001-03-21 Glaxo Group Ltd Compounds
WO2002094317A1 (en) * 2001-05-18 2002-11-28 Endacea Inc. Methods and formulations of using a1 adenosine and p2x purinoreceptor antagonists
GB0112348D0 (en) * 2001-05-19 2001-07-11 Smithkline Beecham Plc Compounds
JP2005504793A (ja) * 2001-09-05 2005-02-17 スミスクライン　ビーチャム　パブリック　リミテッド　カンパニー Ｒａｆキナーゼ阻害剤としてのヘテロサイクルカルボキサミド誘導体
WO2003048140A1 (en) 2001-12-03 2003-06-12 Japan Tobacco Inc. Azole compound and medicinal use thereof
AR038966A1 (es) * 2002-03-18 2005-02-02 Solvay Pharm Bv Derivados de tiazol que tienen actividad antagonista, agonista o agonista parcial de cb1
MXPA05002332A (es) 2002-09-18 2005-06-08 Pfizer Prod Inc Nuevos compuestos de oxazol y tiazol como inhibidores del factor de crecimiento transformador (tgf).
JP2006502236A (ja) * 2002-09-18 2006-01-19 ファイザー・プロダクツ・インク 形質転換成長因子（ｔｇｆ）阻害剤としてのトリアゾール誘導体
RU2332412C2 (ru) * 2003-02-07 2008-08-27 Дайити Фармасьютикал Ко., Лтд. Производные пиразола
AR044519A1 (es) 2003-05-02 2005-09-14 Novartis Ag Derivados de piridin-tiazol amina y de pirimidin-tiazol amina
GB0326601D0 (en) * 2003-11-14 2003-12-17 Novartis Ag Organic compounds
TWI349550B (en) * 2003-12-26 2011-10-01 A thiazole derivative and adenosine a2a receptor antagonist containing the same
US20050227989A1 (en) * 2004-04-13 2005-10-13 Icagen, Inc. Polycyclic thiazoles as potassium ion channel modulators
SG155924A1 (en) * 2004-09-22 2009-10-29 Lundbeck & Co As H 2-acylaminothiazole derivatives
EP1894930A4 (de) 2005-06-23 2010-06-23 Kyowa Hakko Kirin Co Ltd Thiazolderivat
DK1921077T3 (en) 2005-08-02 2017-10-23 Kyowa Hakko Kirin Co Ltd Means for treating and / or preventing sleep disorders
AU2006290814B2 (en) 2005-09-13 2012-06-07 Janssen Pharmaceutica N.V. 2-aniline-4-aryl substituted thiazole derivatives
PE20110371A1 (es) 2006-08-15 2011-06-24 Novartis Ag COMPUESTOS HETEROCICLICOS QUE MODULAN LA ACTIVIDAD DE LA ESTEROIL-CoA-DESATURASA
TW200815428A (en) * 2006-08-15 2008-04-01 Wyeth Corp Oxazolidone derivatives as PR modulators
US7618989B2 (en) * 2006-08-15 2009-11-17 Wyeth Tricyclic oxazolidone derivatives useful as PR modulators
JP2011500625A (ja) 2007-10-18 2011-01-06 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ トリ置換された１，２，４−トリアゾール
JO2784B1 (en) 2007-10-18 2014-03-15 شركة جانسين فارماسوتيكا ان. في 5,3,1 - Triazole substitute derivative
JP2011506560A (ja) 2007-12-20 2011-03-03 ノバルティス アーゲー Ｐｉ３キナーゼ阻害剤として用いられるチアゾール誘導体
CA2715947C (en) 2008-02-20 2016-10-25 Novartis Ag Heterocyclic inhibitors of stearoyl-coa desaturase
AR070936A1 (es) 2008-03-19 2010-05-12 Janssen Pharmaceutica Nv 1,2,4 -triazoles trisustituidos
JP5486591B2 (ja) 2008-05-09 2014-05-07 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ アセチルコリン受容体モジュレーターとしての三置換ピラゾール
US20110190324A1 (en) * 2008-07-16 2011-08-04 Edward Leung Methods of treating atherosclerosis
UA104147C2 (uk) 2008-09-10 2014-01-10 Новартис Аг Похідна піролідиндикарбонової кислоти та її застосування у лікуванні проліферативних захворювань
TWI435874B (zh) * 2008-10-31 2014-05-01 Toray Industries 環己烷衍生物及其醫藥用途
EP2198710A1 (de) 2008-12-19 2010-06-23 Bayer CropScience AG Verwendung von 5-Pyridin-4yl-(1,3)Thiazole zur Bekämpfung phytopathogener Pilze
US8293753B2 (en) 2009-07-02 2012-10-23 Novartis Ag Substituted 2-carboxamide cycloamino ureas
KR101786818B1 (ko) 2010-07-30 2017-10-18 도레이 카부시키가이샤 신경장애성 동통의 치료제 또는 예방제
DE102011083259A1 (de) * 2011-09-23 2013-03-28 Beiersdorf Ag Alkylamidothiazole, deren kosmetische oder dermatologische Verwendung sowie kosmetische oder dermatologische Zubereitungen mit einem Gehalt an solchen Alkylamidothiazolen
WO2015002926A1 (en) 2013-07-02 2015-01-08 Bristol-Myers Squibb Company Tricyclic pyrido-carboxamide derivatives as rock inhibitors
JP6434968B2 (ja) 2013-07-02 2018-12-05 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｒｏｃｋ阻害剤としての三環式ピリド−カルボキサミド誘導体
US9453002B2 (en) 2013-08-16 2016-09-27 Janssen Pharmaceutica Nv Substituted imidazoles as N-type calcium channel blockers
ES2578363B1 (es) 2015-01-22 2017-01-31 Palobiofarma, S.L. Moduladores de los receptores A3 de adenosina
CN108495852B (zh) * 2016-09-08 2021-06-15 四川科伦博泰生物医药股份有限公司 2-酰氨基噻唑类衍生物及其制备方法与用途
ES2676535B1 (es) 2017-01-20 2019-04-29 Palobiofarma Sl Moduladores de los receptores a3 de adenosina
CN109293652B (zh) * 2017-07-24 2021-10-22 四川科伦博泰生物医药股份有限公司 一种取代的噻唑衍生物及其用途
CN107400124A (zh) * 2017-09-14 2017-11-28 刘双伟 一种烟酰胺类化合物、合成路线及其在制备抗过敏药物中的应用
IL297963A (en) 2020-05-07 2023-01-01 Adorx Therapeutics Ltd Antagonists of the adenosine a2a receptor
TW202334117A (zh) 2020-08-24 2023-09-01 美商達薩瑪治療公司 Ｓａｒｍ１之抑制劑

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2828091A1 (de) * 1978-06-27 1980-01-10 Boehringer Sohn Ingelheim 4-substituierte thiazoloxamsaeuren sowie ihre salze und ester
US4251535A (en) * 1978-08-29 1981-02-17 E. I. Du Pont De Nemours And Company Antiinflammatory 4,5-diaryl-2-nitroimidazoles
US4199592A (en) * 1978-08-29 1980-04-22 E. I. Du Pont De Nemours And Company Antiinflammatory 4,5-diaryl-2-nitroimidazoles
DE2856909A1 (de) 1978-12-28 1980-07-17 Schering Ag Neue imidazolderivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische praeparate
JPS6058981A (ja) * 1983-09-09 1985-04-05 Takeda Chem Ind Ltd ５−ピリジル−１，３−チアゾ−ル誘導体，その製造法およびそれを含んでなる医薬組成物
EP0149884B1 (de) * 1983-09-09 1992-12-16 Takeda Chemical Industries, Ltd. 5-Pyridyl-1,3-Thiazol-Derivate, ihre Herstellung und Anwendung
DE3601411A1 (de) * 1986-01-20 1987-07-23 Nattermann A & Cie 3-amino-1-(2-thiazolyl)-2-pyrazoline, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische praeparate
ATE137805T1 (de) * 1989-02-14 1996-05-15 Wako Pure Chem Ind Ltd Verfahren zur erhöhung von chemilumineszenz
DK0513387T3 (da) * 1990-11-30 2000-06-05 Otsuka Pharma Co Ltd Thiazolderivater som inhibitorer af aktivt oxygen
JP2600644B2 (ja) * 1991-08-16 1997-04-16 藤沢薬品工業株式会社 チアゾリルベンゾフラン誘導体
JPH0570446A (ja) * 1991-09-13 1993-03-23 Taisho Pharmaceut Co Ltd Ｎ−チアゾリルスルホンアミド誘導体
GB9201692D0 (en) 1992-01-27 1992-03-11 Smithkline Beecham Intercredit Compounds
BR9306190A (pt) * 1992-04-01 1998-06-23 Univ Toledo Composto composiçao farmacéutica e processo para tratar um indivíduo sofrendo de um distúrbio cognitivo ou uma deficiéncia na atençao ou estímulo
US5486526A (en) * 1992-04-01 1996-01-23 The University Of Toledo Histamine H3 -receptor antagonists and therapeutic uses thereof
CA2132724A1 (en) * 1992-04-10 1993-10-28 Robert Zamboni Thiazole-substituted benzyl alcohols as leukotriene antagonists
US5670527A (en) * 1993-07-16 1997-09-23 Smithkline Beecham Corporation Pyridyl imidazole compounds and compositions
US5783664A (en) * 1993-09-17 1998-07-21 Smithkline Beecham Corporation Cytokine suppressive anit-inflammatory drug binding proteins
WO1995011681A1 (en) * 1993-10-29 1995-05-04 Merck & Co., Inc. Human adenosine receptor antagonists
US5646156A (en) 1994-04-25 1997-07-08 Merck & Co., Inc. Inhibition of eosinophil activation through A3 adenosine receptor antagonism
US5620999A (en) * 1994-07-28 1997-04-15 Weier; Richard M. Benzenesulfonamide subtituted imidazolyl compounds for the treatment of inflammation
US5739143A (en) * 1995-06-07 1998-04-14 Smithkline Beecham Corporation Imidazole compounds and compositions
US5972980A (en) * 1995-10-05 1999-10-26 Warner-Lambert Company Method for treating and preventing inflammation and atherosclerosis
WO1997012613A1 (en) * 1995-10-05 1997-04-10 Warner-Lambert Company Method for treating and preventing inflammation and atherosclerosis
US6001866A (en) * 1995-10-05 1999-12-14 Warner-Lambert Company Method for treating and preventing inflammation and atherosclerosis
US6083949A (en) * 1995-10-06 2000-07-04 Merck & Co., Inc. Substituted imidazoles having anti-cancer and cytokine inhibitory activity
US5717100A (en) * 1995-10-06 1998-02-10 Merck & Co., Inc. Substituted imidazoles having anti-cancer and cytokine inhibitory activity
US5756499A (en) * 1996-01-11 1998-05-26 Smithkline Beecham Corporation Substituted imidazole compounds
WO1997033879A1 (en) 1996-03-15 1997-09-18 Merck & Co., Inc. Compounds and methods for selectively inhibiting activation of the human a3 adenosine receptor
WO1997035855A1 (en) * 1996-03-25 1997-10-02 Smithkline Beecham Corporation Novel treatment for cns injuries
WO1997035856A1 (en) * 1996-03-25 1997-10-02 Smithkline Beecham Corporation Novel treatment for cns injuries
JP2000511173A (ja) * 1996-05-27 2000-08-29 藤沢薬品工業株式会社 一酸化窒素産生阻害剤としての新規なインドリルおよびベンゾフラニルカルボキサミド
WO1998007425A1 (en) * 1996-08-21 1998-02-26 Smithkline Beecham Corporation Imidazole compounds, compositions and use
JPH1087490A (ja) * 1996-09-10 1998-04-07 Sagami Chem Res Center インターロイキン６生産抑制剤、骨吸収抑制剤、抗骨粗鬆症剤、及びチアゾール化合物
US5891892A (en) * 1996-10-29 1999-04-06 Warner-Lambert Company Small molecule biaryl compounds as inhibitors of endothelin converting enzyme
WO1998021957A1 (en) * 1996-11-20 1998-05-28 Merck & Co., Inc. Triaryl substituted imidazoles, compositions containing such compounds and methods of use
HUP0002842A3 (en) * 1997-04-24 2002-01-28 Ortho Mcneil Pharm Inc Substituted imidazoles, process for producing them, pharmaceutical compositions containing them, their use and their intermediates
AU8757098A (en) * 1997-06-30 1999-02-10 Ortho-Mcneil Pharmaceutical, Inc. 2-substituted imidazoles useful in the treatment of inflammatory diseases
JPH11145279A (ja) * 1997-10-27 1999-05-28 Shijie Xianjin Jiti Electric Co Ltd 窒化シリコン保護膜のピンホール除去方法
JPH11193281A (ja) * 1997-10-27 1999-07-21 Takeda Chem Ind Ltd アデノシンａ３受容体拮抗剤およびチアゾール化合物

Also Published As

Publication number Publication date
EP1027050B1 (de) 2004-01-14
US6436966B1 (en) 2002-08-20
DE69821132D1 (de) 2004-02-19
EP1027050A2 (de) 2000-08-16
US6620825B1 (en) 2003-09-16
DE69821132T2 (de) 2004-10-21
CA2302417A1 (en) 1999-05-06
AU9648098A (en) 1999-05-17
WO1999021555A2 (en) 1999-05-06
JPH11193281A (ja) 1999-07-21
WO1999021555A3 (en) 1999-07-22

Similar Documents

Publication Publication Date Title
DE69821132T2 (de) 1,3-thiazole als adenosine a3 rezeptor antagonisten zur behandlung von asthma, allergien und diabetes
DE69926806D1 (de) N-ureidoalkylpiperidine als modulatoren der aktivität der chemokinrezeptoren
DE69926919D1 (de) N-ureidoalkylpiperidine als modulatoren der aktivität der chemokinrezeptoren
DE60023492D1 (de) Glucagon antagonisten/inverse agonisten
DE69918296D1 (de) N-substituierte aminotetraline als neuropeptid y y5 rezeptor-liganden und ihre anwendung zur behandlung von fettleibigkeit und anderen erkrankungen
DE69706407D1 (de) META-SUBSTITUIERTE PHENYLENDERIVATE UND IHRE VERWENDUNG ALS ALPHAvBETA3 INTERGRIN-ANTAGONISTEN ODER INHIBITOREN
DK0714392T3 (da) Heterocykliske neurokinin-antagonister
IL96891A0 (en) Indole-substituted five-membered heteroaromatic compounds,their preparation and pharmaceutical compositions containing them
ATE293989T1 (de) Verwendung von eph-rezeptor-antagonisten und agonisten zur behandlung von vaskulären krankheiten
DE69922676D1 (de) N-aralkylaminotetraline als neuropeptid-y-y5-rezeptorliganden
NZ516599A (en) 2-arylimino-2,3-dihydrothiazoles, and their use thereof as somatostatin receptor ligands
DE60037726D1 (de) Carbonsäurederivate die die bindung von integrinen an ihre rezeptoren hemmen
SE9703414D0 (sv) New compounds
HUP0103203A2 (hu) Azaadamantánszármazékok és ezeket tartalmazó gyógyszerkészítmények
HK1044483A1 (zh) Il-8受体拮抗剂
ATE178886T1 (de) 1-aryl-2-acylamino-ethan-verbindungen und ihre verwendung als neurokinin- insbesondere als neurokinin-1-antagonisten
ES2088128T3 (es) Aminosulfonilureas inhibidoras de acat.
EE200100520A (et) N-(2-fenüül-4-aminobutüül)-1-naftamiidid neurokiniin-1-retseptori antagonistidena
ATE260278T1 (de) 5ht1 rezeptor antagonisten und ihre verwendung für die behandlung von depression
NO963331L (no) 5-Heteroarylindol-derivater som benzodiazepin-reseptorsete-agonister og antagonister
DE69819742D1 (de) Indolderivate als 5-ht1b und 5-ht1d agonisten
ATE189894T1 (de) Naphthamidderivate von 3-beta-amino azabicyclooctan oder nonan als antipsychotische arzneimittel
DE3578125D1 (de) Formulierung von entzuendungshemmenden arzneimitteln.
HK1044717A1 (zh) Il-8受体拮抗剂
FI971831A0 (fi) Heterosyklillä substituoituja propeenihappojohdannaisia NMDA-antagonisteina

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties